1. AB0270 Treatment response to rituximab in combination with leflunomide is influenced by anticcp status in active rheumatoid arthritis: results from a multicenter randomised placebo-controlled investigator initiated clinical trial in active rheumatoid arthritis (AMARA-STUDY). (12th June 2018) Authors: Köhm, M.; Rossmanith, T.; Alten, R.; Aringer, M.; Backhaus, M.; Burmester, G.; Feist, E.; Herrmann, E.; Kellner, H.; Lehn, A.; Müller-Ladner, U.; Rubbert-Roth, A.; Tony, H.-P.; Wassenberg, S.; Burkhardt, H.; Behrens, F. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 1315 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. AB0467 Rapid achievement of remission with certolizumab pegol was maintained for one year: interim results from fast, a german non-interventional study in rheumatoid arthritis real life patients. (23rd January 2014) Authors: Burmester, G.; Müller-Ladner, U.; Nüsslein, H.; von Hinuber, U.; Edelmann, E.; Detert, J.; Höhle, M.; Richter, C.; Klopsch, T.; Kumke, T.; Fricke, D. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 664 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. AB0741 Detection of Psoriatic Arthritis in Patients with Psoriasis in Daily Routine Care Using Questionnaires for Diagnosis of Psoriatic Arthritis and Fluorescence-Optical Imaging Technique: Diagnostic Value for Detection of Subclinical Signs of Musculoskeletal Inflammation in Psoriasis?. (15th July 2016) Authors: Köhm, M.; Rossmanith, T.; Langer, H.-E.; Burmester, G.; Wassenberg, S.; Kaesser, U.; Backhaus, M.; Burkhardt, H.; Behrens, F. Journal: Annals of the rheumatic diseases Issue: Volume 75(2016)Supplement 2 Page Start: 1158 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. AB1150 The european reference network on rare and complex connective tissue and musculoskeletal diseases: ern reconnet. (12th June 2018) Authors: Mosca, M.; Cutolo, M.; Badreh, S.; Bombardieri, S.; Burmester, G.; Fonseca, J.E.; Frank, C.; Galetti, I.; Hachulla, E.; Houssiau, F.; Müller-Ladner, U.; Schneider, M.; Smith, V.; van Laar, J. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 1679 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. FRI0145 The effect of adalimumab on risk of major adverse cardiovascular events in rheumatoid arthritis: A meta-analysis of randomized trials. (23rd January 2014) Authors: Burmester, G.; Emery, P.; Signorovitch, J.; Williams, D.; Valdes, J.; Bao, Y.; Mulani, P.M. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 359 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. FRI0159 Long-term effectiveness and safety of adalimumab in patients with moderate versus severe rheumatoid arthritis. (23rd January 2014) Authors: Burmester, G.; Matucci-Cerinic, M.; Navarro-Blasco, F.; Oezer, U.; Kary, S.; Unnebrink, K.; Kupper, H. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 365 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. FRI0199 Rituximab in Combination with Leflunomide: Results from A Multicenter Randomized Placebo Controlled Investigator Initiated Clinical Trial in Active Rheumatoid Arthritis (Amara-Study). (15th July 2016) Authors: Behrens, F.; Rossmanith, T.; Köhm, M.; Alten, R.; Aringer, M.; Backhaus, M.; Baerwald, C.; Burmester, G.; Feist, E.; Kellner, H.; Krüger, K.; Müller-Ladner, U.; Rubbert-Roth, A.; Tony, H.-P.; Wassenberg, S.; Burkhardt, H. Journal: Annals of the rheumatic diseases Issue: Volume 75(2016)Supplement 2 Page Start: 502 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. FRI0216 Long-Term Safety and Efficacy of Mavrilimumab, A Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor-Alpha Monoclonal Antibody, in Patients with Rheumatoid Arthritis. (15th July 2016) Authors: Burmester, G.; McInnes, I.; Kremer, J.; Miranda, P.; Vencovský, J.; Godwood, A.; Albulescu, M.; Close, D.; Weinblatt, M. Journal: Annals of the rheumatic diseases Issue: Volume 75(2016)Supplement 2 Page Start: 510 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. FRI0232 Consistent efficacy and safety outcomes between european and japanese subjects with rheumatoid arthritis following treatment with mavrilimumab in the phase 2 earth study. (23rd January 2014) Authors: Burmester, G.; Takeuchi, T.; Barbarash, O.; Ranganna, G.; Close, D.; Godwood, A.; Saurigny, D. Journal: Annals of the rheumatic diseases Issue: Volume 72:Supplement 3(2013) Page Start: A451 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. FRI0316 The Efficacy and Safety of Subcutaneous Tocilizumab versus Intravenous Tocilizumab in Combination with Traditional DMARDS in Patients with RA at Week 97 (SUMMACTA). (10th June 2014) Authors: Burmester, G.; Rubbert-Roth, A.; Cantagrel, A.; Hall, S.; Leszczynski, P.; Feldman, D.; Rangaraj, M.J.; Roane, G.; Ludivico, C.; Mysler, E.; Bennett, M.J.; Rowell, L.; Bao, M. Journal: Annals of the rheumatic diseases Issue: Volume 73:Supplement 2(2014) Page Start: 499 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗